Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	34.32B
Revenue (ttm)	1.24B
Net Income (ttm)	765.39M
Shares Out	616.79M
EPS (ttm)	1.24
PE Ratio	44.84
Forward PE	112.05
Dividend	0.12 (0.22%)
Ex-Dividend Date	Jun 13, 2025

Volume	6,689,259
Average Volume	8,171,219
Open	55.95
Previous Close	55.20
Day's Range	54.65 - 57.25
52-Week Range	16.31 - 68.68
Beta	0.70
RSI	53.16
Earnings Date	Aug 30, 2025

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 995
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.